Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.35 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19344220 | 1.00 | CYP2A6 (0.39) | CYP2A6ACVRL1DOT1LPOLRMTMAP4K4 | |
| SCHEMBL19343962 | 1.00 | CYP2A6 (0.39) | CYP2A6ACVRL1DOT1LPOLRMTMAP4K4 | |
| SCHEMBL18667150 | 1.00 | CYP2A6 (0.39) | CYP2A6ACVRL1DOT1LPOLRMTMAP4K4 | |
| SCHEMBL20834955 | 0.90 | DOT1L (0.35) | CYP2A6ACVRL1DOT1LPOLRMTMAP4K4 | |
| SCHEMBL19344234 | 0.88 | CYP2A6 (0.39) | CYP2A6ACVRL1DOT1LPOLRMTMAP4K4 | |
| SCHEMBL24058306 | 0.86 | POLRMT (0.35) | DOT1LPOLRMTMAP4K4STING1TNIK | |
| SCHEMBL23959828 | 0.83 | CYP2A6 (0.38) | CYP2A6 | |
| SCHEMBL24606310 | 0.82 | DOT1L (0.36) | DOT1LPOLRMTPIK3CD | |
| SCHEMBL24340458 | 0.82 | POLRMT (0.43) | DOT1LPOLRMT | |
| SCHEMBL22355531 | 0.82 | POLRMT (0.43) | DOT1LPOLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389750-A1 | NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF HAVING VIRAL GROWTH INHIBITORY ACTION | Shionogi & Co., Ltd. (JP) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023115796-A1 | NEW CRYSTAL FORM OF NUCLEOSIDE COMPOUND AND SALT THEREOF | 深圳安泰维生物医药有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023011994-A1 | PROCESS FOR THE CATALYTIC GLYCOSYLATION OF ARENES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2023-02-09 | — | — | WO | disclosed |
| EP-4130001-A1 | PROCESS FOR THE DIRECT CATALYTIC GLYCOSYLATION OF ARENES | Studiengesellschaft Kohle mbH (DE) | 2023-02-08 | — | — | EP | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| EP-3505173-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | CYP2A6 1074/4885ACVRL1 2646/4885DOT1L 1151/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | CYP2A6 3758/4885ACVRL1 4215/4885DOT1L 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.